Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis - 29/08/11
the study group*
Abstract |
Background: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. Objective: We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone dipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone. Methods: This was an international, multicenter, prospective, randomized, double-blind, parallel-group, 4-week study in patients with psoriasis vulgaris amenable to topical treatment. Results: The mean percentage reduction in PASI from baseline to end of treatment was 73.2% in the combination group (n = 301), 48.8% in the calcipotriene group (n = 308), 63.1% in the betamethasone dipropionate group (n = 312) and 28.8% in the new vehicle group (n = 107), (P < .001). The mean percentage reduction in PASI during the first week was 48.1%, 28.4%, 41.4%, and 21.5%, respectively (P < .001). Conclusion: A combination product of calcipotriene 50 μg/g and betamethasone dipropionate 0.5 mg/g in the new vehicle shows superior efficacy with a more rapid onset of action than the new vehicle containing either constituent alone in the treatment of psoriasis vulgaris. (J Am Acad Dermatol 2003;48:48-54.)
Le texte complet de cet article est disponible en PDF.Plan
*The members of the study group are listed at the end of this article. |
|
Funding sources: The reported clinical study was entirely supported by Leo Pharmaceutical Products. |
|
Disclosure: Mr Talbot is employed by Leo Pharmaceutical Products. None of the authors has any stock, equity or other potential financial conflict of interest in Leo Pharmaceutical Products, which is owned entirely by the Leo Foundation, an independent private institution. |
|
Reprint requests: Kim A. Papp, MD, Probity Medical Research, 135 Union St East, Waterloo, Ontario N2J 1C4 Canada. E-mail: kapapp@probitymedical.com. |
|
♢ | 0190-9622/2003/$30.00 + 0 |
Vol 48 - N° 1
P. 48-54 - janvier 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?